Morbid Book Review: Saul Justin Newman Debunks Blue Zones
Nov 11, 2026
Morbid: Debunking Modern Longevity Science by Saul Justin Newman (MIT Press, 2026, 296 pages, $29.95) argues that much of what we think we know about extreme longevity rests on bad data. Its targets include record-holding supercentenarians, the famous “Blue Zones,” and antiaging products sold with more confidence than evidence. The publisher calls it “a darkly comedic journey into the science of aging,” and the description fits.
Our verdict in this Morbid book review: Morbid is an entertaining and useful corrective for anyone who follows longevity news, and it belongs on the shelf next to more optimistic books like those on our recommended reading list. Read it, however, knowing that its central Blue Zones argument rests on research that has not yet appeared in a peer-reviewed journal and that other demographers dispute.
About the author: Saul Justin Newman
Saul Justin Newman is a Senior Research Fellow at University College London’s Centre for Longitudinal Studies and a Research Fellow at the University of Oxford’s Institute of Population Ageing, and he has spent years checking the paperwork behind the world’s oldest people. In 2024, he won the first Ig Nobel Prize in Demography, awarded to research that “makes people laugh, and then think,” for work suggesting that many extreme-age records reflect clerical errors and pension fraud.
His best-known peer-reviewed paper appeared in PLOS Biology in 2018. It showed that tiny error rates in recorded ages, below 1 in 10,000, are enough to create the apparent “plateau” in death rates at very old ages. Some researchers had read that plateau as a hint that human lifespan has no fixed limit. Newman argued instead that correcting the errors removes it, and that human aging does not slow in extreme old age.
His follow-up work on supercentenarians and Blue Zones is more provocative. It remains a preprint, meaning other scientists have not formally reviewed it in a published journal. According to the preprint itself, it passed peer review at BMC Public Health but has not been published there.
What Morbid covers: longevity myths, Blue Zones, and antiaging hype
The book moves through three broad subjects: the people said to be the oldest in the world, the places said to produce long lives, and the products said to extend them.
The world’s oldest people
Newman opens, according to the publisher’s description, with a petition to exhume a famous corpse, and he argues that the world’s oldest man is a fake. The case he builds is that extreme-age records depend on paperwork, and paperwork is easy to get wrong or to fake. Science News reviewer Meghan Rosen highlights one example: a woman counted as a validated centenarian who had in fact died, while her son kept collecting her pension with her body in a freezer. Newman’s question, as Rosen quotes it: “Could most of the world’s oldest people be just … shonky data?”
Blue Zones
Chapter 6, “Yeti-Hunting in the Blue Zones,” is the book’s centerpiece and its case that the Blue Zones are debunked. Newman traces the idea from a study of a few Sardinian villages, through Dan Buettner’s National Geographic cover story and trademark, to today’s certification business. He also reminds readers that this has happened before. The “longevity zones” of the 1970s, in Georgia’s Abkhazia region, Pakistan’s Hunza Valley, and Ecuador’s Vilcabamba, collapsed once outside scientists checked ages; in Vilcabamba, one supposed 132-year-old turned out to be 95.
Newman then tests the core claim against government statistics. In European Union rankings of survival past age 85 across 128 regions, he reports that Sardinia was tied for 51st in 1990 and the region containing Ikaria was 109th; by 2021 they sat around 36th to 44th and 56th to 65th. Loma Linda, California, falls between the 27th and 75th percentiles of US neighborhoods in life expectancy estimates from the Centers for Disease Control and Prevention. After Japan’s 2010 audit of missing centenarians, he places Okinawa around 26th of 47 prefectures for late-life survival.
Loma Linda, the only US Blue Zone, fares worst of all. Beyond its middling life expectancy, Newman notes that millions of Seventh-day Adventists live elsewhere under the same religious health practices (the church counted 23.7 million members worldwide at the end of 2024), yet none of their communities earned the label. Even Buettner appears to concede the point: citing The New York Times, Newman reports that Buettner called Loma Linda “kind of an outlier,” said it was included because his National Geographic editor wanted an American Blue Zone, and admitted he had never bothered to remove it from the list. STAT reported a similar account in 2026. The church connection runs deeper still. Adventist Health, a Seventh-day Adventist health system based in Roseville, California, bought Blue Zones LLC in 2020 for a reported $78 million, so the brand is now owned by the same faith whose community anchors its weakest zone. Newman also flags the awkward fit between Adventists’ commitment to sobriety and a brand that recommends daily wine.
Singapore, the newest Blue Zone, gets its own treatment. Newman points out that Singapore did not make birth certificates universal until 1938, so no one can verify how many Singaporeans truly reach 100. Instead, its Blue Zone status rests on a different yardstick: health-adjusted life expectancy, an estimate of years lived in good health, on which Singapore ranked first in one lab’s estimate. Newman argues that the goalposts moved for this one zone, and he quotes Singapore’s own health minister describing a poor national diet and a stressed pace of life that look nothing like the Blue Zones script. Our take: health-adjusted life expectancy is a legitimate public health measure, but it answers a different question than how many people reach 100, and a high score for a wealthy city-state with strong public health systems is not surprising.
The most striking pages set the Blue Zones’ nine lifestyle tips beside Japanese government surveys of Okinawa. By Newman’s account, Okinawans have had the highest average body mass index in Japan since measurements began in 1975, eat about 40 kilograms of meat a year, rank last of 47 prefectures for sweet potatoes and leafy vegetables, are the least religious prefecture, and rank second in the country for beer drinking. He saves particular scorn for the “Wine at 5” advice of one to two glasses a day, which he notes is double UK guidance. The math checks out: the National Health Service counts a standard 175-milliliter glass of 12% wine as 2.1 units, so two glasses a day add up to about 29 units a week, roughly double its 14-unit weekly limit.
The chapter closes on money. Beyond the Adventist Health purchase, Newman cites Sharecare’s ownership of the Blue Zones Project, towns paying millions of dollars for certification, and program results measured with a well-being index that Sharecare itself owns. In his words, the company is effectively scoring “the benefits of their own program.”
The antiaging business
The book’s third target is the industry selling longer life. The publisher’s description mentions a billionaire’s scheme to tap the blood of Texas teenagers and an episode in which a Central Intelligence Agency (CIA) operative accused Newman of spying for Russia. Rosen notes that Newman also criticizes heavily funded antiaging compounds such as resveratrol and scientists who start companies selling supplements based on their own unproven research. His summary advice, as quoted in her review: “Sack the charlatans, laugh out anyone who promises a ‘cure’ to aging or carries a trademark.”
Why we age
Finally, Newman lays out mathematical and evolutionary explanations for why people age and die, with chapters touching on telomeres, cell recycling, and evolutionary fitness. For our own overview of those mechanisms, see What Causes Aging?
Strengths: a funny, skeptical guide to longevity claims
Morbid is, by reviewers’ accounts, fun to read, which is rare for a book about statistics and death. Rosen calls it “a thrilling ride” and credits Newman’s “enviable skill in statistics.” Reviewers at The Guardian, The New Yorker, and The Wall Street Journal were similarly positive, with The New Yorker’s Dhruv Khullar calling the book “lively and sometimes conspiratorial” and its criticisms “pointed” and “useful.”
More importantly, the book teaches a habit worth having: check the data before you believe the headline. Rosen sums up its lesson as “You can’t believe everything you read,” even in prestigious journals. Readers who spend money on longevity products, from anti-aging dietary supplements to premium testing services, will come away asking better questions.
Newman’s peer-reviewed work also backs part of his larger point. His 2018 PLOS Biology paper showed that small recording errors can manufacture an apparent slowdown in aging at extreme ages, which supports his broader claim that bad data has shaped how scientists think about the limits of human life.
The Blue Zones chapter shows the book’s method at its best. Newman quotes each claim, then sets it beside a government statistic with a footnote you can check. That format is persuasive and easy to follow, and the alcohol section in particular is a useful correction to advice that has circulated for two decades.
Limitations of Morbid and the case for Blue Zones
The Blue Zones case is disputed
The book’s most quotable claim, that Blue Zones are largely a product of bad records, has the weakest formal support. Newman’s Blue Zones research remains a preprint. Meanwhile, Blue Zones researchers have answered him in a peer-reviewed journal. In “The validity of Blue Zones demography: a response to critiques”, published in The Gerontologist in December 2025, Steven Austad of the University of Alabama at Birmingham and Giovanni Pes of the University of Sassari defend the age checks behind each zone. In Sardinia, they write, every nonagenarian and centenarian’s age was double-checked against civil records dating to 1866, church archives, and family trees. In Costa Rica’s Nicoya region, ages had to match across a birth registry, the electoral roll, and death records, and a 2007 field check of 35 supposed centenarians removed one. For Japan, they cite the 2012 analysis finding about 600 truly missing centenarians nationwide and none in Okinawa.
The rebuttal has gaps of its own. It does not engage with Newman’s specific methods, his European survival rankings, or the Okinawa body mass index and diet data at the heart of Chapter 6. It concedes that “a certain degree of economic underdevelopment” has historically characterized the Blue Zones. Readers should also know that Pes is one of the researchers who identified the original Blue Zones and joined Buettner on the 2007 Nicoya visit, though the paper declares no conflicts of interest.
Neither side has the last word yet. Still, readers should know that Morbid presents one side of a live scientific argument, not a settled verdict. Austad’s own summary applies in both directions: “Extraordinary claims about longevity demand extraordinary evidence.”
Population averages are not centenarians
Much of Newman’s lifestyle evidence comes from prefecture- and region-wide averages for today’s population, not from the diets and habits of the specific people who reached 100. A centenarian born around 1910 may have lived very differently from the average Okinawan surveyed in recent decades. Newman partly answers this with body mass index data reaching back to 1975 and surveys from the 1970s, but those still describe whole populations, not the oldest residents.
Some numbers also need context. Newman writes that at least 82% of Japanese centenarians “turned out to be imaginary or dead” in 2010. The underlying event is real: Japan’s Justice Ministry found 234,354 people aged 100 or older still listed as alive in family registers who could not be confirmed. However, a peer-reviewed analysis in Demographic Research explains that these were old register entries that had never been crossed out, not people counted in Japan’s official centenarian statistics, and that their effect on life expectancy figures was “effectively nil.” That fits the Austad and Pes finding of roughly 600 truly missing centenarians in the official counts. Newman’s broader point about unreliable records stands, but the 82% figure overstates how badly Japan’s official data were affected.
The biology chapters are thinner
Rosen found that the book “loses some steam” when it moves from data detective work into the biology of aging, leaving her “with more questions than answers.” Brandy Schillace, writing in The Wall Street Journal, noted that Newman “doesn’t ultimately answer whether humans have a set age limit,” though he argues the science needs firming up before anyone can.
The tone is not for everyone
Newman calls himself a “cheeky scamp,” and Rosen observes that he “is not out to make friends.” Readers who enjoy a takedown will relish it. Readers looking for a balanced survey of longevity science, or practical health advice, should pair it with other books.
In the Blue Zones chapter, many of the jokes land on Dan Buettner personally, from his Guinness World Records claims to his early career, and on side characters such as Dr. Mehmet Oz. They are funny, but they add little to the data argument and may lead skeptical readers to dismiss the evidence along with the tone.
What Morbid means for your longevity choices
If Newman is right about Blue Zones, it does not follow that diet, exercise, sleep, and social ties stop mattering. His critique targets where the famous records came from, not research on everyday habits. The case for those basics, which we summarize in 7 Immediate Ways to Increase Healthspan, never depended on a few remote villages.
What the book should change is how you judge new claims. Before you buy a product or a test, ask four questions:
- Was the finding published in a peer-reviewed journal, or only in a preprint, press release, or podcast?
- How many people were studied, and for how long?
- Does the person making the claim sell something tied to it?
- Has anyone outside the original team repeated the result?
Those questions apply as much to anti-aging companies and biological age tests as to Blue Zones. They also apply to Morbid itself, which is exactly the spirit Newman asks for. For the bigger debate over how far human lifespan can stretch, see Live to 100 or Live to 1000?
Disclosure: Keep.Health purchased its own copy of Morbid for this review and receives no commissions from the publisher or booksellers.
Frequently asked questions
What is Morbid by Saul Justin Newman about?
Morbid: Debunking Modern Longevity Science, published by MIT Press in 2026, argues that much longevity science rests on bad data. Saul Justin Newman challenges extreme-age records, the Blue Zones, and antiaging products, and he explains why humans age, all with a darkly comic tone that reviewers have widely praised.
Are Blue Zones real?
The question is unsettled. Saul Justin Newman argues that Blue Zone longevity largely reflects record errors and pension fraud, but that research is still a preprint. Blue Zones researchers defend their age checks in a peer-reviewed 2025 paper in The Gerontologist. Either way, healthy habits do not depend on the answer.
Who is Saul Justin Newman?
Saul Justin Newman is a research fellow at University College London and the University of Oxford who studies the accuracy of extreme-age records. He won the 2024 Ig Nobel Prize in Demography for work linking supercentenarian claims to clerical errors and pension fraud, and he published a 2018 PLOS Biology paper on how recording errors distort old-age death rates.
Is Morbid worth reading?
Yes, for readers who follow longevity news and want a sharper eye for weak claims. It is entertaining and well reviewed. Treat its Blue Zones argument as one side of an open debate, and expect its chapters on the biology of aging to raise more questions than they answer.
